← Leaderboards
Shelli R McAlpine
San Diego State University
$1,448,228
Attributed
$1,448,228
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $357.7K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$1,448,228 · 2
By mechanism
R01$1,297,228 · 1
R03$151,000 · 1
Top collaborators
No co-investigators on record.
Most similar at San Diego State University
Same institution · by research overlap
- Samantha S Orchard$94,772
Others in their field
Top investigators on “C-Terminal”
- Hao Wu · Harvard Medical School$21,988,652
- Alan N. Engelman · Dana-Farber Cancer Institute$14,919,380
- Timothy A Springer · Boston Children'S Hospital$14,558,332
- Luciano D'adamio · Rutgers Biomedical And Health Sciences$13,918,810
- Stephen Buratowski · Harvard Medical School$13,108,547
- Daniel L Minor · University Of California San Francisco$13,023,064
Research focus
C-TerminalCytotoxicColon Cancer Cell LineColonAnalogAntitumor AgentAmino AcidsBinding (Molecular Function)Binding SitesAffectBiological FactorsAntineoplastic AgentsCancer Cell LineCancer TypeBaseCell Cycle ProgressionCell LineCell PhysiologyCellular TargetingCharacteristicsChemotherapeutic AgentBiologicalClientCytotoxicity
Grant awards (7)
Conformational based design and development of antitumor agents$296,393
R01 · FY2012 · CA · contact PI
Conformational based design and development of antitumor agents$305,938
R01 · FY2011 · CA · contact PI
Conformational based design and development of antitumor agents$51,724
R01 · FY2011 · CA · contact PI
Conformational based design and development of antitumor agents$315,400
R01 · FY2010 · CA · contact PI
Conformational based design and development of antitumor agents$327,773
R01 · FY2009 · CA · contact PI
Novel Antibiotics:Site-Specific Recombination Inhibitors$75,500
R03 · FY2005 · AI
Novel Antibiotics: Site-Specific Recombination Inhibitor$75,500
R03 · FY2004 · AI